Tocilizumab Plus a Short Prednisone Taper for GCA

• Status: Recruiting
• Trial end date: 2022-02-01

Summary

This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.

• Phase: Phase 4

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Roche-Genentech
• Treatments: Glucocorticoids; Prednisone